Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | BCR | P11274 | 2/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580218 | 0.88 | AURKB (0.39) | KMT2ASELPTYRO3HCRTR1MEN1 | |
| SCHEMBL4378862 | 0.83 | KMT2A (0.45) | KMT2ATYRO3MEN1AURKBAURKA | |
| SCHEMBL4378859 | 0.83 | KMT2A (0.45) | KMT2ATYRO3MEN1AURKBAURKA | |
| SCHEMBL22501580 | 0.82 | SELP (0.43) | KMT2ASELPTYRO3MEN1JAK1 | |
| SCHEMBL4549835 | 0.82 | STK17B (0.43) | KMT2AHCRTR1ABL1BCR | |
| SCHEMBL29437412 | 0.82 | STK17B (0.43) | KMT2AHCRTR1ABL1BCR | |
| SCHEMBL3574419 | 0.80 | AURKB (0.39) | KMT2ASELPTYRO3MEN1AURKB | |
| SCHEMBL22501744 | 0.80 | KMT2A (0.40) | KMT2ASELPTYRO3MEN1ABL1 | |
| SCHEMBL22553562 | 0.80 | KMT2A (0.40) | KMT2ASELPTYRO3MEN1ABL1 | |
| SCHEMBL4577037 | 0.80 | KMT2A (0.43) | KMT2ASELPTYRO3MEN1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10927120-B2 | CDK inhibitors | GI Therapeutics, Inc. (NC) | 2021-02-23 | — | — | US | disclosed |
| US-20200277300-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2016040848-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2968291-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2967050-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968290-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144847-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | KMT2A 276/4885SELP 4806/4885TYRO3 2955/4885 |
| US-20200277300-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | KMT2A 276/4885SELP 4806/4885TYRO3 2955/4885 |
| US-10927120-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | KMT2A 276/4885SELP 4806/4885TYRO3 2955/4885 |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | KMT2A 513/4885SELP 3392/4885TYRO3 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.